Amgen, Inc. (AMGN)
467.06
-1.05
(-0.22%)
USD |
NASDAQ |
Nov 12, 16:00
469.13
+2.07
(+0.44%)
After-Hours: 05:16
Amgen Free Cash Flow (Quarterly) : 3.654B for Sept. 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 3.654B |
| June 30, 2026 | 3.489B |
| March 31, 2026 | 1.477B |
| December 31, 2025 | 961.00M |
| September 30, 2025 | 4.248B |
| June 30, 2025 | 1.911B |
| March 31, 2025 | 980.00M |
| December 31, 2024 | 4.40B |
| September 30, 2024 | 3.314B |
| June 30, 2024 | 2.221B |
| March 31, 2024 | 459.00M |
| December 31, 2023 | 289.00M |
| September 30, 2023 | 2.512B |
| June 30, 2023 | 3.838B |
| March 31, 2023 | 720.00M |
| December 31, 2022 | 2.309B |
| September 30, 2022 | 2.818B |
| June 30, 2022 | 1.684B |
| March 31, 2022 | 1.974B |
| December 31, 2021 | 2.521B |
| September 30, 2021 | 2.176B |
| June 30, 2021 | 1.746B |
| March 31, 2021 | 1.938B |
| December 31, 2020 | 1.98B |
| September 30, 2020 | 3.233B |
| Date | Value |
|---|---|
| June 30, 2020 | 2.684B |
| March 31, 2020 | 1.992B |
| December 31, 2019 | 2.326B |
| September 30, 2019 | 3.207B |
| June 30, 2019 | 1.27B |
| March 31, 2019 | 1.729B |
| December 31, 2018 | 2.969B |
| September 30, 2018 | 3.102B |
| June 30, 2018 | 1.915B |
| March 31, 2018 | 2.572B |
| December 31, 2017 | 2.859B |
| September 30, 2017 | 3.296B |
| June 30, 2017 | 2.141B |
| March 31, 2017 | 2.217B |
| December 31, 2016 | 2.774B |
| September 30, 2016 | 2.594B |
| June 30, 2016 | 2.39B |
| March 31, 2016 | 1.759B |
| December 31, 2015 | 1.855B |
| September 30, 2015 | 2.736B |
| June 30, 2015 | 2.681B |
| March 31, 2015 | 1.211B |
| December 31, 2014 | 2.107B |
| September 30, 2014 | 2.571B |
| June 30, 2014 | 2.054B |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Gilead Sciences, Inc. | 4.798B |
| Regeneron Pharmaceuticals, Inc. | 1.427B |
| AbbVie, Inc. | 7.305B |
| Biogen, Inc. | 375.40M |
| Vertex Pharmaceuticals, Inc. | 545.80M |